GH Research (GHRS) Competitors $8.46 +0.26 (+3.17%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends GHRS vs. EVO, ARQT, RCUS, NRIX, KNSA, IMCR, OCUL, MESO, NTLA, and TVTXShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Evotec (EVO), Arcutis Biotherapeutics (ARQT), Arcus Biosciences (RCUS), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), Mesoblast (MESO), Intellia Therapeutics (NTLA), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Evotec Arcutis Biotherapeutics Arcus Biosciences Nurix Therapeutics Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Intellia Therapeutics Travere Therapeutics GH Research (NASDAQ:GHRS) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends. Do analysts recommend GHRS or EVO? GH Research currently has a consensus target price of $35.67, suggesting a potential upside of 321.59%. Evotec has a consensus target price of $5.93, suggesting a potential upside of 24.13%. Given GH Research's stronger consensus rating and higher possible upside, equities analysts plainly believe GH Research is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Evotec 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Do institutionals & insiders believe in GHRS or EVO? 56.9% of GH Research shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Comparatively, 1.0% of Evotec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is GHRS or EVO more profitable? Evotec's return on equity of 0.00% beat GH Research's return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -20.29% -19.49% Evotec N/A N/A N/A Which has more risk and volatility, GHRS or EVO? GH Research has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Which has higher earnings and valuation, GHRS or EVO? GH Research has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$35.59M-$0.79-10.71Evotec$777.05M2.18-$90.82MN/AN/A Does the media refer more to GHRS or EVO? In the previous week, Evotec had 5 more articles in the media than GH Research. MarketBeat recorded 5 mentions for Evotec and 0 mentions for GH Research. GH Research's average media sentiment score of 1.76 beat Evotec's score of 0.65 indicating that GH Research is being referred to more favorably in the media. Company Overall Sentiment GH Research Very Positive Evotec Positive Does the MarketBeat Community believe in GHRS or EVO? GH Research received 18 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 72.73% of users gave GH Research an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformGH ResearchOutperform Votes2472.73% Underperform Votes927.27% EvotecOutperform Votes654.55% Underperform Votes545.45% SummaryGH Research beats Evotec on 9 of the 14 factors compared between the two stocks. Ad Porter & CompanyMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$440.16M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-10.7110.75135.1917.53Price / SalesN/A287.861,232.15140.37Price / CashN/A56.6540.6537.95Price / Book1.715.394.884.92Net Income-$35.59M$152.04M$118.97M$225.78M7 Day Performance-1.63%-4.32%15.41%-1.58%1 Month Performance-10.67%2.80%15.47%6.67%1 Year Performance60.84%17.30%34.58%22.48% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research1.9124 of 5 stars$8.46+3.2%$35.67+321.6%+51.3%$440.16MN/A-10.7110Positive NewsEVOEvotec1.4795 of 5 stars$4.69+4.5%$5.93+26.5%-56.6%$1.66B$777.05M0.005,061Short Interest ↓ARQTArcutis Biotherapeutics0.7957 of 5 stars$13.35+5.2%$15.50+16.1%+509.0%$1.56B$138.71M-7.58150Options VolumeNews CoverageRCUSArcus Biosciences2.5772 of 5 stars$16.39+1.9%$34.00+107.4%-11.3%$1.50B$117M-5.11500NRIXNurix Therapeutics2.8431 of 5 stars$21.08+4.0%$30.35+44.0%+133.3%$1.49B$56.42M-6.97300KNSAKiniksa Pharmaceuticals2.6661 of 5 stars$20.33+0.6%$36.60+80.0%+13.9%$1.47B$384.10M-147.36220Positive NewsIMCRImmunocore2.6216 of 5 stars$28.88-0.1%$65.64+127.3%-54.2%$1.44B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.797 of 5 stars$9.02+3.8%$16.71+85.3%+129.5%$1.42B$58.44M0.00267Positive NewsMESOMesoblast1.0319 of 5 stars$12.09+2.8%$11.50-4.9%+484.6%$1.38B$5.90M0.0080News CoverageGap UpNTLAIntellia Therapeutics4.1809 of 5 stars$13.50+4.7%$54.94+306.9%-57.3%$1.37B$36.28M-2.37600Short Interest ↑TVTXTravere Therapeutics2.7223 of 5 stars$17.60+1.6%$22.62+28.5%+97.9%$1.37B$145.24M-3.81460Positive News Related Companies and Tools Related Companies Evotec Alternatives Arcutis Biotherapeutics Alternatives Arcus Biosciences Alternatives Nurix Therapeutics Alternatives Kiniksa Pharmaceuticals Alternatives Immunocore Alternatives Ocular Therapeutix Alternatives Mesoblast Alternatives Intellia Therapeutics Alternatives Travere Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GHRS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GHRS Stock Alerts